Prokaryotics
Dr. Silhavy is the Warner-Lambert Parke-Davis Professor of Molecular Biology at Princeton University. His area of expertise includes the bacterial genetics of Gram-negative cell envelope biogenesis.
This person is not in the org chart
This person is not in any offices
Prokaryotics
Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.